Aligos Stock Analysis

ALGS -  USA Stock  

USD 25.89  0.69  2.60%

The latest price spike of Aligos Therapeutics could raise concerns from retail investors as the firm it trading at a share price of 25.89 on 207,200 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.43. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Aligos Therapeutics partners.
Please continue to Trending Equities.

Search Stock Analysis 

The Aligos Therapeutics stock analysis report makes it easy to digest most publicly released information about Aligos Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aligos stock analysis module also helps to analyze the Aligos Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Aligos Stock Analysis Notes

About 20.0% of the company shares are held by company insiders. The company had not issued any dividends in recent years. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. For more info on Aligos Therapeutics please contact the company at 800 466 6059 or go to

Aligos Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aligos Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aligos Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aligos Therapeutics is way too risky over 90 days horizon
Aligos Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 910 K. Net Loss for the year was (116.19 M).
Aligos Therapeutics currently holds about 213.42 M in cash with (83.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59.
Aligos Therapeutics has a poor financial position based on the latest SEC disclosures
Over 76.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Hirth Peter of 15000 shares of Aligos Therapeutics subject to Rule 16b-3

Aligos Largest EPS Surprises

Earnings surprises can significantly impact Aligos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Aligos Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aligos Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aligos Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aligos Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
10th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
3rd of May 2021
Unclassified Corporate Event
27th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
23rd of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of February 2021
Unclassified Corporate Event
11th of February 2021
Unclassified Corporate Event
11th of January 2021
Unclassified Corporate Event
30th of October 2020
Unclassified Corporate Event

Aligos Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aligos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aligos Therapeutics backward and forwards among themselves. Aligos Therapeutics' institutional investor refers to the entity that pools money to purchase Aligos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon SharesM90.8 M
Vivo Capital LlcCommon Shares3.5 M80.7 M
Versant Venture Management LlcCommon Shares3.3 M74.9 M
Novo Holdings ACommon Shares2.6 M59.5 M
Hillhouse Capital Advisors LtdCommon Shares2.2 M49.2 M
Janus Henderson Group PlcCommon Shares2.2 M48.7 M
Baker Bros Advisors LpCommon Shares1.6 M36.6 M
Note, although Aligos Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aligos Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.28 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aligos Therapeutics's market, we take the total number of its shares issued and multiply it by Aligos Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Aligos Profitablity

Aligos Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Aligos Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Aligos Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aligos Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aligos Therapeutics' profitability requires more research than a typical breakdown of Aligos Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.53) (0.57) 
Return on Average Equity(1.40) (1.44) 
Return on Invested Capital(1.88) (2.03) 

Management Efficiency

The entity has return on total asset (ROA) of (38.3) % which means that it has lost $38.3 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (74.38) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics management efficiency ratios could be used to measure how well aligos therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2021, Return on Average Assets is likely to drop to -0.57. In addition to that, Return on Average Equity is likely to drop to -1.44. Aligos Therapeutics Assets Non Current are relatively stable at the moment as compared to the past year. Aligos Therapeutics reported last year Assets Non Current of 15.29 Million. As of 06/19/2021, Tangible Assets Book Value per Share is likely to grow to 35.06, while Total Assets are likely to drop slightly above 239.9 M.
Last ReportedProjected for 2021
Book Value per Share 22.03  23.77 
Enterprise Value over EBIT(9.90) (10.68) 
Enterprise Value over EBITDA(9.86) (10.64) 
Price to Book Value 4.31  4.28 
Tangible Assets Book Value per Share 26.56  35.06 
Enterprise Value931.4 M926 M
Tangible Asset Value265.3 M239.9 M

Technical Drivers

As of the 19th of June, Aligos Therapeutics shows the Mean Deviation of 4.94, risk adjusted performance of 0.1522, and Downside Deviation of 5.87. Aligos Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Aligos Therapeutics, which can be compared to its rivals. Please confirm Aligos Therapeutics information ratio, as well as the relationship between the potential upside and kurtosis to decide if Aligos Therapeutics is priced correctly, providing market reflects its regular price of 25.89 per share. Given that Aligos Therapeutics has jensen alpha of 0.5359, we suggest you to validate Aligos Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Aligos Therapeutics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of one hundred fifty-seven. The Mid-point over period is an average of Aligos Therapeutics highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Aligos Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aligos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aligos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aligos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aligos Therapeutics Predictive Daily Indicators

Aligos Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aligos Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aligos Therapeutics Forecast Models

Aligos Therapeutics time-series forecasting models is one of many Aligos Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aligos Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Aligos Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aligos Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aligos shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Aligos Therapeutics. By using and applying Aligos Stock analysis, traders can create a robust methodology for identifying Aligos entry and exit points for their positions.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.

Current Aligos Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aligos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aligos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
36.75Strong Buy4Odds
Aligos Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aligos analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aligos stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aligos Therapeutics, talking to its executives and customers, or listening to Aligos conference calls.
Aligos Analyst Advice Details

Aligos Stock Analysis Indicators

Aligos Therapeutics stock analysis indicators help investors evaluate how Aligos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aligos Therapeutics shares will generate the highest return on investment. By understating and applying Aligos Therapeutics stock analysis, traders can identify Aligos Therapeutics position entry and exit signals to maximize returns.
Quick Ratio8.46
Fifty Two Week Low12.82
Shares Short Prior Month1.6M
Average Daily Volume Last 10 Day106.04k
Average Daily Volume In Three Month72.81k
Shares Percent Shares Out4.22%
Short Percent Of Float10.98%
Forward Price Earnings-9.80
Float Shares15.3M
Fifty Two Week High37.51
Enterprise Value To Ebitda-9.49
Fifty Day Average26.86
Two Hundred Day Average25.42
Enterprise Value To Revenue1,061.75
Please continue to Trending Equities. Note that the Aligos Therapeutics information on this page should be used as a complementary analysis to other Aligos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Aligos Therapeutics Stock analysis

When running Aligos Therapeutics price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Transaction History
View history of all your transactions and understand their impact on performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
The market value of Aligos Therapeutics is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aligos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos Therapeutics' market value can be influenced by many factors that don't directly affect Aligos Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aligos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.